Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

The U.S. Food and Drug Administration is now requiring two common COVID-19 vaccines to update their warning labels to include ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...